Efficacy and safety of glucagon-like Peptide-1 receptor agonists in the treatment of metabolic associated fatty liver disease: a systematic review and Meta-analysis
SELECT Trial - New England Journal of Medicine : The pivotal trial demonstrating 20% cardiovascular event reduction with semaglutide in people with obesity but without diabetes, establishing the cardioprotective effect independent of glucose-lowering
It is important to focus on safety, effectiveness, and your own health needs
Paul Edison, a professor of neuroscience at Imperial College London, who led another study testing a similar drug to treat Alzheimers and has also consulted for Novo Nordisk
The central role of glutathione in the pathophysiology of human diseases
Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis